4.1 Introduction

High-dose chemotherapy and autologous hematopoietic stem cell transplantation (HSCT) is the standard treatment for some hematologic malignancies, especially multiple myeloma (MM), lymphoma (Hodgkin’s and non-Hodgkin’s), and acute myeloid leukemia (AML). Infection represents an important cause of morbidity after autologous HSCT, but its frequency and etiology depends on the presence of various risk factors.

The risk of infection in autologous HSCT recipients is the result of the interaction between the host, pathogens, and environmental exposure. Infections develop when an imbalance occurs between the weakened protective defense mechanisms of the host and the virulence factors of the offending pathogen. Table 4.1 presents a list of
**Table 4.1** Risk factors for infection after high-dose chemotherapy and autologous hematopoietic stem cell transplantation

| Risk factor for infection                                  | Risk category                  |
|------------------------------------------------------------|--------------------------------|
| **1. Pretransplant**                                       |                                |
| *General condition including organ function*               |                                |
| Performance status                                         | Good                           |
| Renal failure                                              | No                             |
| Diabetes mellitus                                          | No                             |
| Iron stores [1]                                            | Normal or decreased            |
| Age                                                        | Younger (<40 years)            |
| Smoking [1]                                                | No                             |
| *Underlying disease and its treatment*                     |                                |
| Tumor burden                                               | None                           |
| Disease-related immunosuppression†                         | Absent                         |
| Prior chemotherapy                                         | None or minimal                |
| Receipt of purine analogues (fludarabine, cladribine, clofarabine) or monoclonal antibodies (rituximab, alemtuzumab) | No                             |
| *Exposure to pathogens*                                    |                                |
| Prior history of infection b                               | No                             |
| Colonization with pathogens (bacteria, fungi)              | No                             |
| *Immunogenetics*                                           |                                |
| Deficiency of MBL [2, 3]                                    | No                             |
| **2. Pre-engraftment period**                              |                                |
| *Duration of neutropenia [1]*                              | Short (<7 days)                |
| Stem cell source                                           | Peripheral blood               |
| Quantity of stem cells infused c                           | >5×10^6/Kg CD34+ cells         |
| Severity of oral and gastrointestinal mucositis            | Absent or mild                 |
| Conditioning regimen                                       | Less intensive                 |
| Polymorphisms of genes associated with metabolism of chemotherapeutic agents (pharmacogenetics) | Absent                         |
| Renal failure d                                            | Absent                         |
| *Exposure to pathogens*                                    |                                |
| Nosocomial exposure to potential pathogens (water and airborne pathogens such as *Legionella, Aspergillus* spp. and other molds, resistant bacteria, respiratory viruses) | No                             |
| **3. Post-engraftment**                                   |                                |
| *T cell immune reconstitution*                             | Fast                           |
| Prior chemotherapy [4]                                     | Minimal                        |
risk factors for infection in the different periods: pretransplant, early pre-engraftment, and post-engraftment period. Assessment of the risk of infection in each period and the identification of patients at higher risk of specific infections are critical to the appropriate management of infectious complications after autologous HSCT.

An important and difficult element of risk assessment in autologous HSCT recipients is to quantify the risk associated with the status of the underlying disease and prior therapies. For example, a patient with MM who undergoes a first autologous HSCT after having received a short course of induction therapy with dexamethasone plus thalidomide and whose disease is under control is at lower risk for certain infections compared with a patient with the same underlying disease, but who is receiving a third or fourth autologous HSCT in the setting of relapse after multiple treatment lines.

### 4.2 Risk for and Epidemiology of Infection

Immunodeficiency is the key risk factor for infection in autologous HSCT recipients. It is a result of interplay between the underlying disease and its therapy and may involve breakdowns in skin and mucous membrane barriers, qualitative and quantitative decrease in the number of functional T cells, and qualitative and quantitative decrease in the number of functional B cells.

#### Table 4.1 (continued)

| Risk factor for infection                                      | Risk category |
|---------------------------------------------------------------|---------------|
| CMV serostatus \([5]\)                                        | Low | High |
| Need for additional chemotherapy to control the underlying disease\(^{e}\) | No | Yes |
| In vitro manipulation of stem cells \([6, 7]\)                 | No | Yes |
| Exposure to pathogens                                         |               |
| Prior history of infection\(^{b}\)                           | No | Yes |
| Community-acquired infections, especially respiratory viruses | No | Yes |

\(^{a}\) Most common disease-related immunosuppression include: hypogammaglobulinemia (multiple myeloma, low-grade B-cell non-Hodgkin’s lymphoma, chronic lymphocytic leukemia), T-cell mediated immunodeficiency (Hodgkin’s lymphoma and certain types of non-Hodgkin’s lymphoma) and neutrophil dysfunction (acute myeloid leukemia with myelodysplasia)

\(^{b}\) Infections with higher risk of recurrence after autologous hematopoietic stem cell transplantation include: mycobacteriosis (tuberculosis and others), aspergillosis, pneumocystosis, cytomegalovirus, herpes simplex and varicella-zoster virus, and toxoplasmosis and strongyloidiasis

\(^{c}\) In vitro manipulation of stem cells decreases the content of CD34+ and T cells, increasing the duration of neutropenia in the early post-transplant period and delaying T cell immune reconstitution after transplant

\(^{d}\) Renal failure increases the risk of severe mucositis in patients with multiple myeloma receiving melphalan-based conditioning regimens

\(^{e}\) Need for additional chemotherapy in lymphoma and acute myeloid leukemia is usually related to relapse of the underlying disease, whereas in multiple myeloma additional chemotherapy is usually part of the treatment strategy

\(M BL\) mannose-binding lectin, \(TL R\) Toll-like receptors, \(CM V\) cytomegalovirus
quantitative defects in various arms of the immune system including innate immunity (neutropenia, neutrophil dysfunction), impaired production of immunoglobulins, and defective cell-mediated immunity (CMI). While autologous HSCT recipients have deficits in various arms of the immune system, the nature of the pathogens causing infection is frequently determined by the immunodeficiency that is predominant at a given time (Tables 4.2 and 4.3).

Pretransplant variables that significantly impact the risk for major infection include host factors such as poor performance status and older age, comorbidities such as diabetes and renal failure [8], iron overload [1], smoking [1], and high tumor burden. In addition, the risk and pattern of infection after autologous HSCT are strongly influenced by the intensity of prior treatment for the underlying disease and the type of treatment. For example, patients who received purine analogues and monoclonal antibodies are at increased risk for specific infections post-transplant [9, 10]. Finally, some genetic polymorphisms in genes linked to the innate immunity are associated with an increased risk of infection. In a series of 113 autologous HSCT for multiple myeloma, patients homozygous for wild-type mannose-binding lectin (MBL) 2 were at lower risk to develop septicemia compared with patients carrying the variant MBL2 [2]. In another study, MBL deficiency was associated with higher risk of bacterial infections [3].
### Table 4.3  Frequent pathogens causing infection according to immunodeficiency

|                          | Disruption of skin and mucous membranes | Hypogammaglobulinemia | T-cell mediated immunodeficiency | Neutropenia and neutrophil dysfunction |
|--------------------------|-----------------------------------------|-----------------------|----------------------------------|---------------------------------------|
| **Bacteria**             |                                         |                       |                                  |                                       |
| **Gram-positive cocci**  |                                         |                       |                                  |                                       |
| Coagulase-negative staphylococci | +++                                    | −                     | −                                | ++                                    |
| *Staphylococcus aureus*  | +++                                     | −                     | −                                | ++                                    |
| Viridans streptococci    | +++                                     | −                     | −                                | ++                                    |
| Enterococci              | ++                                      | −                     | −                                | ++                                    |
| *Streptococcus pneumoniae* | −                                      | +++                  | −                                | −                                     |
| **Gram-positive bacilli** |                                         |                       |                                  |                                       |
| *Bacillus spp.*          | ++                                      | −                     | +                                | ++                                    |
| *Corynebacterium jeikeium* | +                                      | −                     | +                                | ++                                    |
| *Listeria monocytogenes* | −                                       | −                     | +++                              | −                                     |
| **Gram-negative bacilli** |                                         |                       |                                  |                                       |
| Enterobacteriaceae<sup>a</sup> | ++                                    | −                     | −                                | +++                                   |
| *Pseudomonas aeruginosa* | +                                       | −                     | −                                | +++                                   |
| Other nonfermentative bacteria<sup>b</sup> | +                                       | −                     | −                                | +++                                   |
| *Salmonella spp.*        | +                                       | +                     | ++                               | +                                     |
| *Legionella spp.*        | −                                       | +                     | ++                               | −                                     |
| **Anaerobes**            |                                         |                       |                                  |                                       |
| *Clostridium difficile*  | ++                                      | −                     | −                                | ++                                    |
| *Clostridium septicum*   | ++                                      | −                     | −                                | ++                                    |
| **Fungi**                |                                         |                       |                                  |                                       |
| **Yeast**                |                                         |                       |                                  |                                       |
| *Candida spp.*<sup>c</sup>, mucosal disease | +                                       | −                     | +++                              | −                                     |
| *Candida spp.*<sup>c</sup>, invasive disease | +                                       | −                     | −                                | +++                                   |
| *Cryptococcus neoformans*<sup>a</sup> | −                                       | −                     | +++                              | −                                     |
| *Trichosporon spp.*      | ++                                      | −                     | +                                | ++                                    |
| **Molds (mainly Aspergillus spp.)<sup>d</sup>** | −                                       | −                     | ++                               | +++                                   |
| **Other**                |                                         |                       |                                  |                                       |
| *Pneumocystis jirovecii* | −                                       | −                     | +++                              | −                                     |
| **Viruses**              |                                         |                       |                                  |                                       |
Table 4.3 (continued)

|                                      | Disruption of skin and mucous membranes | Hypogammaglobulinemia | T-cell mediated immunodeficiency | Neutropenia and neutrophil dysfunction |
|--------------------------------------|----------------------------------------|-----------------------|----------------------------------|---------------------------------------|
| Herpes simplex                       | ++                                     | −                     | +++                              | ++                                    |
| Varicella-zoster                     | −                                      | −                     | +++                              | −                                     |
| Cytomegalovirus                      | −                                      | −                     | +++                              | −                                     |
| Epstein-Barr virus                   | −                                      | +                     | +++                              | −                                     |
| Respiratory viruses<sup>a</sup>      | +                                      | +                     | +++                              | −                                     |
| Hepatitis A, B and C                 | −                                      | +                     | +                                | −                                     |
| Parovirus B 19                       | −                                      | ++                    | ++                               | −                                     |
| **Parasites**                        |                                        |                       |                                  |                                       |
| Strongyloides stercoralis            | −                                      | −                     | ++                               | −                                     |
| Toxoplasma gondii                    | −                                      | −                     | ++                               | −                                     |
| Cryptosporidium parvum               | −                                      | +                     | ++                               | −                                     |
| **Mycobacteria**                     |                                        |                       |                                  |                                       |
| Mycobacterium tuberculosis           | −                                      | −                     | +++                              | −                                     |
| Rapid growing mycobacteria           | ++                                     | −                     | +                                | −                                     |
| Mycobacterium avium complex          | −                                      | −                     | +++                              | −                                     |

(−) no. (+) occasional, (+++) frequent, (+++) very frequent
<sup>a</sup>Most frequent: *Escherichia coli*, *Klebsiella pneumoniae*, *Enterobacter* spp;
<sup>b</sup>Most frequent: *Acinetobacter* spp., *Stenotrophomonas maltophilia*;
<sup>c</sup>Most frequent: *C. albicans*, *C. glabrata*, *C. tropicalis*, *C. parapsilosis*;
<sup>d</sup>Most frequent: *A. fumigatus* (~90 %), *A. flavus*, *A. terreus*, *A. niger*;
<sup>e</sup>Most frequent: Respiratory syncytial virus, metapneumovirus, influenza A and B, parainfluenza 1–3, adenovirus, rhinovirus, coronavirus

### 4.2.1 Pre-Engraftment Period

The main risk factors for infection in the pre-engraftment period are neutropenia, oral and gastrointestinal mucositis, and the presence of central venous catheters. In general, infection occurs more frequently with longer periods of neutropenia [1], and a decrease in the rates of bacteremia has been observed with the utilization of peripheral blood, instead of marrow, as the source of stem cells [11]. In addition, severe mucositis is associated with increasing risk for infection [6, 12], and indwelling venous catheters, present in virtually all ASCT recipients during the early period, may predispose to certain bloodstream infections [13].

The majority of bacterial infections during neutropenia are caused by Gram-positive organisms; *Staphylococci* (coagulase-negative and *S. aureus*), viridans *Streptococci* and the *Enterococci*; Gram-negative bacteria including the Enterobacteriaceae *Escherichia coli*, *Klebsiella* spp. and *Enterobacter* spp., and the nonfermentative bacteria *Pseudomonas aeruginosa*, *Acinetobacter* spp. and *Stenotrophomonas maltophilia* [14, 15]. In addition, patients with severe mucositis
are at increased risk to develop bloodstream infections caused by anaerobes [16], alpha-hemolytic streptococci [17, 18], *Stenotrophomonas maltophilia* [19], vancomycin-resistant enterococci [20], and *Candida* spp [21, 22].

Considerable shifts in the spectrum of bacterial infections have occurred over time as a result of antimicrobial prophylaxis therapy with more severely mucotoxic drugs [23] and the widespread use of intravascular catheters. Until the late 1980s, Gram-positive and Gram-negative organisms were equally distributed as causes of bloodstream infections. The introduction of quinolone prophylaxis was associated with a significant reduction in Gram-negative infections [24] but at the cost of an increase in infections caused by Gram-positive bacteria. A reemergence of bacteremia by resistant Gram-negative organisms has been recently observed [25–27] including quinolone-resistant Enterobacteriaceae [28], extended-spectrum c-lactamase (ESBL)-producing bacteria (Enterobacteriaceae, *P. aeruginosa*, *Acinetobacter* spp., others) [29], multidrug-resistant *P. aeruginosa*, and others [30]. Infections by resistant Gram-positive organisms have also been noted with vancomycin-resistant enterococci (VRE) and nosocomial and community-acquired methicillin-resistant *S. aureus* (MRSA) [31, 32]. A more serious problem in neutropenic patients with leukemia is the marked increase in *Clostridium difficile* colitis [33, 34]. In a retrospective study in 242 autologous HSCT recipients, 157 developed diarrhea between 1 week before and 30 days after HSCT, and 135 were tested for *C. difficile* toxin A. A diagnosis of *C. difficile*-associated diarrhea (CDAD) was made in 21 subjects (15.5 %) and occurred both before (4 patients) and after (17 patients) transplant. Patients receiving mobilization with paclitaxel and growth factor were at lower risk for CDAD compared with patients mobilized with growth factors with or without cyclophosphamide. Receipt of vancomycin or cephalosporins were risk factors for CDAD [35].

Great variability exists, between and within countries, in the etiology of bacterial infections and their susceptibility profiles [36], and an intimate knowledge of the local epidemiology remains critical in applying strategies of prophylaxis, empiric antibiotic therapy, and treatment of established infection. In a study of bacteremias in 519 HSCT recipients from a single institution, Gram-positive and Gram-negative bacteria accounted for 62 and 38 % of bacteremias, respectively [26]. The rates of bacteremias decreased over the 7-year study period, but were particularly more pronounced for Gram-positive bacteria, with a drop in the ratio of Gram-positive to Gram-negative organisms from 2.7 to 1.3.

In a prospective survey of 411 HSCT in 13 Brazilian centers, 91 patients developed bacteremia in the early post-transplant period: 47 % were caused by Gram-positive, 37 % due to Gram-negative, and 16 % were due to both Gram-positive and Gram-negative bacteria. *Pseudomonas aeruginosa* (22 %), *K. pneumoniae* (19 %) and *E. coli* (17 %) were the most frequent bacteria among Gram-negative; among Gram-positive bacteria, coagulase-negative staphylococci (50 %) and *S. aureus* (23 %) accounted for the majority of infections. Multi-drug-resistant (MDR) Gram-negative bacteria were isolated in 22 % of bacteremias (5 % of all transplants), and receipt of third-generation cephalosporins was an independent risk factor for infection due to MDR bacteria [37].

During the early post-transplant period, gastrointestinal mucositis and neutropenia predispose to the occurrence of invasive candidiasis, and unless patients are receiving
fluconazole prophylaxis, this is the leading invasive fungal infection in this period. With the introduction of fluconazole prophylaxis, the incidence of candidiasis decreased dramatically, with a shift in species distribution; fewer infections due to *C. albicans* and *C. tropicalis*, but increased infections caused by *C. glabrata* and *C. krusei* [38]. This may be illustrated by three epidemiologic studies. A prospective study of 16,200 HSCTs (autologous and allogeneic) in 23 centers in the USA (Transnet database) reported 217 cases of invasive candidiasis (1.3%). *C. glabrata* was the most frequent species, accounting for 32% of cases. Invasive candidiasis was diagnosed within 30 days after autologous HSCT in 66% of cases, and within 4 months in 74% of cases [39]. In a retrospective study involving 11 centers in Italy, only 16 cases of invasive candidiasis were reported among 1979 autologous HSCTs (0.8%). Eight of the 16 cases were caused by *C. glabrata* (*n*=5) or *C. krusei* (*n*=3) [40].

Invasive aspergillosis occurs typically in patients with profound (<100 neutrophils/mm³) and prolonged (>10–15 days) neutropenia. Because the duration of neutropenia after autologous HSCT is shorter, the incidence of invasive aspergillosis is low. However, patients with concomitant severe CMI deficiency are at risk. This group is represented by patients with lymphoma previously treated with purine analogues [41] and heavily pretreated myeloma patients [42]. We recently analyzed a cohort of 113 patients with multiple myeloma who developed invasive aspergillosis (data not published). Sixty-three episodes occurred after autologous HSCT, at a median of 16 days after transplant. In 29 of the 63 episodes (46%), invasive aspergillosis occurred in the pre-engraftment period. Most patients had relapsed myeloma, had been heavily pretreated, and had received high doses of corticosteroids (median cumulative dose in the last 60 days of 1,380 mg patients, prednisone equivalent).

In the Transnet database, a total of 80 cases of invasive aspergillosis were diagnosed in 9534 autologous HSCT recipients (0.8%). Forty cases were diagnosed within 30 days after transplant [39]. In the Italian retrospective study, seven cases were diagnosed in 1979 autologous HSCT recipients (0.3%) [40]. Except for candidiasis and aspergillosis, other invasive fungal infections are rare.

Viral infections in the early post-transplant period are limited to reactivation of herpes simplex virus (HSV) and respiratory viral infections (Influenza A and B, parainfluenza 1–3, respiratory syncytial virus [RSV], metapneumovirus, and adenovirus). In the absence of prophylaxis (acyclovir or valacyclovir), most autologous HSCT recipients will develop reactivation of HSV, manifested as oral ulcers [43, 44]. The occurrence of symptomatic HSV disease is particularly frequent in patients with severe oral mucositis [45]. Although in most cases the disease is self-limited, causing pain and discomfort, it may evolve to pneumonia as a result of aspiration of the oral secretions with the virus [46].

### 4.2.2 Post-engraftment Period

Although the frequency and mortality of infection after engraftment are much lower than in the early pre-engraftment period, infection is a significant cause of morbidity and an important cause of non-relapse mortality. In a retrospective
analysis of 1,482 autologous HSCT, 32% of non-relapse deaths occurring after
day +100 post-transplant were caused by infectious complications. Sepsis and
pneumonia were the most frequent infections, and viral and fungal disease were
rare causes of death [47].

The risk for infection in the post-engraftment period is a function of the dynam-
ics of immune reconstitution. Factors that delay immune reconstitution following
ASCT are related to the underlying disease and/or to the stem cell product
(Table 4.1). The most important factors influencing the speed of immune reconstitu-
tion are the immune status before HSCT and the need for additional immunosup-
pressive treatment. Heavily pretreated patients who exhibit severe immunodeficiency
before HSCT are at greater risk of infectious complications. Likewise, additional
chemotherapy after HSCT greatly increases the risk of infection. This is true for
patients with MM, who receive consolidation and maintenance after HSCT.

The occurrence of neutropenia increases the risk for infection after engraftment.
In a study, receipt of rituximab was an independent risk factor for delayed onset
neutropenia [9]. Receipt of rituximab pretransplant has also been associated with an
increased risk for CMV reactivation post-transplant [10].

In vitro manipulation of stem cells is usually associated with depletion of T cells
from the harvest and results in delayed immune reconstitution and an increased risk
for fungal, viral, and protozoal infections [48–52]. The influence of in vitro manipula-
tion of stem cells on the risk of infection may be illustrated by a study of 148 patients,
which reported that high T-cell content in the graft was associated with a lower inci-
dence of varicella-zoster virus (VZV) reactivation [6] and another study of autologous
HSCT for autoimmune disease. A 64% CMV reactivation was observed with in vitro
CD34 selection [7]. However, in a study in patients with lymphoma, MM and breast
cancer, the incidence and causes of infection were not different among patients receiv-
ing unmanipulated or CD34 selected peripheral blood stem cells [53].

The frequency and etiology of infections occurring after engraftment were assessed
in 244 autologous HSCT recipients with non-Hodgkin’s lymphoma (n=207),
Hodgkin’s lymphoma (n=27), and MM (n=43). Infection occurred in 64 patients
(26%). The most frequent infections were VZV disease (56%) and bronchopneumo-
nia (25%). By multivariate analysis, receipt of fludarabine was the only variable asso-
ciated with infection [4]. In another study in 127 patients with breast cancer, among 99
patients with prolonged follow up, 32 (32%) developed infection in the first year post-
transplant. Upper respiratory infection (n=11) and dermatomic VZV disease (n=9)
were the most frequent infections. Bacteremia occurred in only two patients [54].

Cytomegalovirus (CMV) reactivation is frequent in the late post-transplant
period. In a retrospective study, 16 of 41 febrile episodes in CMV seropositive
patients were associated with CMV reactivation. CMV infection was the sole cause
of fever [55]. In a prospective study in 171 autologous HSCT recipients, weekly
CMV antigenemia was performed from engraftment until day +60 post-transplant.
Forty of 102 (39%) CMV seropositive patients presented CMV reactivation at a
median of 32 days after transplant. The majority of patients (n=30) were asym-
ptomatic. Fever (n=5) and enteritis (n=5) were the clinical manifestations in the
remaining patients [5].
In addition to VZV and CMV, respiratory viral infections are frequent in autologous HSCT recipients and may contribute to significant morbidity, especially in patients with lymphopenia [56].

Less frequent infections in the post-transplant period include hepatitis B and C [57], toxoplasmosis [58], tuberculosis [59, 60] and pneumocystosis, [61] and, in certain areas of the globe, Chagas disease [62].

4.3 Summary

Infection represents an important cause of morbidity after autologous HSCT. Infection results from an imbalance between host defenses and the pathogen, and the risk vary according to the phase of HSCT. Pretransplant variables that significantly impact the risk for major infection include host factors, genetic predisposition, comorbid conditions, tumor burden and the type, and duration and intensity of prior chemo- or radiotherapy. After HSCT and before engraftment, significant risk factors include neutropenia, mucositis, and central venous catheters. In the post-engraftment period, the risk of infection depends on the dynamics of the immune reconstitution that follows HSCT. Assessment of the risk of infection in each period and the identification of patients at higher risk of specific infections are critical to the appropriate management of infectious complications after autologous HSCT.

References

1. Miceli MH, Dong L, Grazziutti ML, et al. Iron overload is a major risk factor for severe infection after autologous stem cell transplantation: a study of 367 myeloma patients. Bone Marrow Transplant. 2006;37:857–64.
2. Molle I, Peterslund NA, Thiel S, Steffensen R. MBL2 polymorphism and risk of severe infections in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation. Bone Marrow Transplant. 2006;38:555–60.
3. Horiuchi T, Gondo H, Miyagawa H, et al. Association of MBL gene polymorphisms with major bacterial infection in patients treated with high-dose chemotherapy and autologous PBSCT. Genes Immun. 2005;6:162–6.
4. Ketterer N, Espinouse D, Chomarat M, et al. Infections following peripheral blood progenitor cell transplantation for lymphoproliferative malignancies: etiology and potential risk factors. Am J Med. 1999;106:191–7.
5. Rossini F, Terruzzi E, Cammarota S, et al. Cytomegalovirus infection after autologous stem cell transplantation: incidence and outcome in a group of patients undergoing a surveillance program. Transpl Infect Dis. 2005;7:122–5.
6. Zambelli A, Montagna D, Da Prada GA, et al. Evaluation of infectious complications and immune recovery following high-dose chemotherapy (HDC) and autologous peripheral blood progenitor cell transplantation (PBPC-T) in 148 breast cancer patients. Anticancer Res. 2002;22:3701–8.
7. Kohno K, Nagafuji K, Tsukamoto H, et al. Infectious complications in patients receiving autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Transpl Infect Dis. 2009;11:318–23.
8. Sheean PM, Freels SA, Helton WS, Braunschweig CA. Adverse clinical consequences of hyperglycemia from total parenteral nutrition exposure during hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006;12:656–64.

9. Kato H, Yamamoto K, Matsuo K, et al. Clinical impact and predisposing factors of delayed-onset neutropenia after autologous hematopoietic stem-cell transplantation for B-cell non-Hodgkin lymphoma: association with an incremental risk of infectious events. Ann Oncol. 2010;21:1699–705.

10. Lee MY, Chiou TJ, Hsiao LT, et al. Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin’s lymphoma patients receiving autologous hematopoietic stem cell transplantation. Ann Hematol. 2008;87:285–9.

11. Nosanchuk JD, Sepkowitz KA, Pearse RN, White MH, Nimer SD, Armstrong D. Infectious complications of autologous bone marrow and peripheral stem cell transplantation for refractory leukemia and lymphoma. Bone Marrow Transplant. 1996;18:355–9.

12. McCann S, Schwenkglenks M, Bacon P, et al. The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT. Bone Marrow Transplant. 2009;43:141–7.

13. Celebi H, Akan H, Akcaglayan E, Ustun C, Arat M. Febrile neutropenia in allogeneic and autologous peripheral blood stem cell transplantation and conventional chemotherapy for malignancies. Bone Marrow Transplant. 2000;26:211–4.

14. Feld R. Bloodstream infections in cancer patients with febrile neutropenia. Int J Antimicrob Agents. 2008;32 Suppl 1:530–3.

15. Dettenkofer M, Wenzler-Rottele S, Babikir R, et al. Surveillance of nosocomial sepsis and pneumonia in patients with a bone marrow or peripheral stem cell blood transplant: a multicenter project. Clin Infect Dis. 2005;40:926–31.

16. Lark RL, McNeil SA, VanderHyde K, Noorani Z, Uberti J, Chenoweth C. Risk factors for anaerobic bloodstream infections in bone marrow transplant recipients. Clin Infect Dis. 2001;33:338–43.

17. Ruescher TJ, Sodeifi A, Scrivani SJ, Kaban LB, Sonis ST. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer. 1998;82:2275–81.

18. Bochud PY, Eggiman P, Calandra T, Van Melle G, Saghafi L, Francioli P. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis. 1994;18:25–31.

19. Labarca JA, Leber AL, Kern VL, et al. Outbreak of Stenotrophomonas maltophilia bacteremia in allogeneic bone marrow transplant patients: role of severe neutropenia and mucositis. Clin Infect Dis. 2000;30:195–7.

20. Kuehnert MJ, Jernigan JA, Pullen AL, Rimland D, Jarvis WR. Association between mucositis severity and vancomycin-resistant enterococcal bloodstream infection in hospitalized cancer patients. Infect Control Hosp Epidemiol. 1999;20:660–3.

21. Bow EJ, Loewen R, Cheang MS, Schacter B. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. Clin Infect Dis. 1995;21:361–9.

22. Bow EJ, Loewen R, Cheang MS, Shore TB, Rubinger M, Schacter B. Cytotoxic therapy-induced D-xylene malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults. J Clin Oncol. 1997;15:2254–61.

23. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis. 1999;29:490–4.

24. Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol. 1998;16:1179–87.

25. Garnica M, Maiolino A, Nucci M. Factors associated with bacteremia due to multidrug-resistant gram-negative bacilli in hematopoietic stem cell transplant recipients. Braz J Med Biol Res. 2009;42:289–93.

26. Collin BA, Leather HL, Wingard JR, Ramphal R. Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin Infect Dis. 2001;33:947–53.
27. Viscoli C, Castagnola E. Treatment of febrile neutropenia: what is new? Curr Opin Infect Dis. 2002;15:377–82.
28. Cattaneo C, Quaresmini G, Casari S, et al. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother. 2008;61:721–8.
29. Trecarichi EM, Tumbarello M, Spanu T, et al. Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect. 2009;58:299–307.
30. Nouer SA, Nucci M, De-Oliveira MP, Pellegrino FL, Moreira BM. Risk factors for acquisition of multidrug-resistant Pseudomonas aeruginosa producing SPM metallo-beta-lactamase. Antimicrob Agents Chemother. 2005;49:3663–7.
31. Rolston KV. Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis. 2005;40 Suppl 4:S246–52.
32. Dubberke ER, Hollands JM, Georgantopoulos P, et al. Vancomycin-resistant enterococcal bloodstream infections on a hematopoietic stem cell transplant unit: are the sick getting sicker? Bone Marrow Transplant. 2006;38:813–9.
33. Dubberke ER, Reske KA, Yan Y, Olsen MA, McDonald LC, Fraser VJ. Clostridium difficile–associated disease in a setting of endemcity: identification of novel risk factors. Clin Infect Dis. 2007;45:1543–9.
34. Schalk E, Bohr UR, Konig B, Scheinplug K, Mohren M. Clostridium difficile–associated diarrhoea, a frequent complication in patients with acute myeloid leukaemia. Ann Hematol. 2010;89:9–14.
35. Arango JI, Restrepo A, Schneider DL, et al. Incidence of Clostridium difficile–associated diarrhoea before and after autologous peripheral blood stem cell transplantation for lymphoma and multiple myeloma. Bone Marrow Transplant. 2006;37:517–21.
36. Maschmeyer G, Haas A. The epidemiology and treatment of infections in cancer patients. Int J Antimicrob Agents. 2008;31:193–7.
37. Oliveira AL, De SM, Carvalho-Dias VM, et al. Epidemiology of bacteremia and factors associated with multi-drug-resistant gram-negative bacteremia in hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2007;39:775–81.
38. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis. 1997;24:1122–8.
39. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50:1091–100.
40. Pagano L, Caira M, Nosari A, et al. Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study–Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis. 2007;45:1161–70.
41. Gil L, Kozlowska-Skrzypczak M, Mol A, Poplawski D, Styczynski J, Komarnicki M. Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT. Bone Marrow Transplant. 2009;43:121–6.
42. Nucci M, Anaissie E. Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis. 2009;49:1211–25.
43. Wade JC, Newton B, Flournoy N, Meyers JD. Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. Ann Intern Med. 1984;100:823–8.
44. Dignani MC, Mykietiuk A, Michelet M, et al. Valacyclovir prophylaxis for the prevention of Herpes simplex virus reactivation in recipients of progenitor cells transplantation. Bone Marrow Transplant. 2002;29:263–7.
45. Ramphal R, Grant RM, Dzoljanovski B, et al. Herpes simplex virus in febrile neutropenic children undergoing chemotherapy for cancer: a prospective cohort study. Pediatr Infect Dis J. 2007;26:700–4.
46. Taplitz RA, Jordan MC. Pneumonia caused by herpesviruses in recipients of hematopoietic cell transplants. Semin Respir Infect. 2002;17:121–9.
47. Jantunen E, Itala M, Siitonen T, et al. Late non-relapse mortality among adult autologous stem cell transplant recipients: a nation-wide analysis of 1,482 patients transplanted in 1990–2003. Eur J Haematol. 2006;77:114–9.

48. Nachbaur D, Fink FM, Nussbaumer W, et al. CD34+-selected autologous peripheral blood stem cell transplantation (PBSC) in patients with low-risk haematological malignancies and solid tumors. A single-centre experience. Bone Marrow Transplant. 1997;20:827–34.

49. Nachbaur D, Kropshofer G, Feichtinger H, Allerberger F, Niederwieser D. Cryptosporidiosis after CD34-selected autologous peripheral blood stem cell transplantation (PBSCT). Treatment with paromomycin, azithromycin and recombinant human interleukin-2. Bone Marrow Transplant. 1997;19:1261–3.

50. Miyamoto T, Gondo H, Miyoshi Y, et al. Early viral complications following CD34-selected autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Br J Haematol. 1998;100:348–50.

51. Rutella S, Pierelli L, Sica S, Rumi C, Leone G. Transplantation of autologous peripheral blood progenitor cells: impact of CD34-cell selection on immunological reconstitution. Leuk Lymphoma. 2001;42:1207–20.

52. Nishio M, Koizumi K, Endo T, Fujimoto K, Koike T, Sawada K. Diminished T-cell recovery after CD34(+) selected autologous peripheral blood stem cell transplantation increases the risk of cytomegalovirus infection. Haematologica. 2001;86:667–8.

53. Frere P, Pereira M, Fillet G, Beguin Y. Infections after CD34-selected or unmanipulated autologous hematopoietic stem cell transplantation. Eur J Haematol. 2006;76:102–8.

54. Barton T, Collis T, Stadtmauer E, Schuster M. Infectious complications the year after autologous bone marrow transplantation or peripheral stem cell transplantation for treatment of breast cancer. Clin Infect Dis. 2001;32:391–5.

55. Fassas AB, Bolanos-Meade J, Buddharaju LN, et al. Cytomegalovirus infection and non-neutropenic fever after autologous stem cell transplantation: high rates of reactivation in patients with multiple myeloma and lymphoma. Br J Haematol. 2001;112:237–41.

56. Martino R, Porras RP, Rabella N, et al. Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies. Biol Blood Marrow Transplant. 2005;11:781–96.

57. Zschiedrich S, Fischer R, Schmitt-Graff A, Blum H, Breidert M. Acute hepatitis after autologous stem cell transplantation and rapid progression to liver cirrhosis. Eur J Gastroenterol Hepatol. 2010;22:1141–4.

58. Gonzalez-Vicent M, Díaz MA, Sevilla J, Madero L. Cerebral toxoplasmosis following etanercept treatment for idiopathic pneumonia syndrome after autologous peripheral blood progenitor cell transplantation (PBPCCT). Ann Hematol. 2003;82:649–53.

59. de la Camara R, Martino R, Granados E, et al. Tuberculosis after hematopoietic stem cell transplantation: incidence, clinical characteristics and outcome. Spanish Group on Infectious Complications in Hematopoietic Transplantation. Bone Marrow Transplant. 2000;26:291–8.

60. Cordonnier C, Martino R, Trabasso P, et al. Mycobacterial infection: a difficult and late diagnosis in stem cell transplant recipients. Clin Infect Dis. 2004;38:1229–36.

61. Chen CS, Boeckh M, Seidel K, et al. Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003;32:515–22.

62. Altclas J, Sinagra A, Dictar M, et al. Chagas disease in bone marrow transplantation: an approach to preemptive therapy. Bone Marrow Transplant. 2005;36:123–9.